Figure 2
From: Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells
GP33 antigen-dependent rejection of orthotopic gliomas in LCMV Arm-infected, but not Cl13-infected mice. (A) Experimental set-up for the orthotopic glioma challenge in LCMV-infected or naive B6 mice. Twenty-one days before tumor challenge, LCMV Arm (acute; triangle) or Cl13 (chronic; diamond) strain were administered to B6 mice. Age-matched naive B6 mice (circle) were used as a comparison. Challenge were glioma cells: CT2A (100,000 cells; dotted line) or CT2A-gp33 (400,000 cells; solid line) which were implanted into the right brains stereotactically for the survival study (shown in B). (B) Survival analyses after orthotopic tumor challenge. Survival was monitored for up to 90 days. Median survival after CT2A challenge (n = 6 in each group) was 15 (naive) and 16 (Arm) days, while median survival after CT2A-gp33 challenge (n = 8 in each group) was 9 (naive), >90 (Arm) and 17 (Cl13) days. Log-rank test was used to compare survival among the LCMV infection (Arm, Cl13) and naïve in CT2A-gp33 challenge groups, or between Arm and Naïve in CT2A challenge groups, ****P < 0.0001.
